Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision
Pfizer and Astellas have received FDA Priority Review for PADCEV plus Keytruda as a perioperative treatment for muscle-invasive bladder cancer, a development that could broaden the treatment population and open new revenue streams for Pfizer. This regulatory milestone provides a fresh perspective for investors following Pfizer, as the company faces valuation debates and a decline in its COVID-related business. Despite positive drug news, the article highlights ongoing concerns about Pfizer’s forecasted earnings declines, dividend coverage, and debt servicing.